[Support of hematological homeostasis during chemotherapy with taxanes]

Vopr Onkol. 2011;57(6):784-8.
[Article in Russian]

Abstract

Study group consisted of 84 oncological patients with various tumor localization that received chemotherapy with taxanes. Medium follow up was 32.1 +/- 2.1 months. All patients had morphologic verification of the process. Distribution according to tumor localization was as follows: breast cancer--60 (71.4%), ovarian cancer--13 (15.5%), lung cancer--7 (8.3%), other localizations--4 (4.8%). Age varied from 22 to 73 years old. All patients had normal hematological status and survival expectation more than 3 months. Hematological complications were mentioned after the first cycle of chemotherapy in 70% cases.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Breast Neoplasms / drug therapy
  • Caproates
  • Docetaxel
  • Female
  • Fever / etiology
  • Fever / prevention & control
  • Follow-Up Studies
  • Homeostasis / drug effects
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / therapeutic use*
  • Lung Neoplasms / drug therapy
  • Male
  • Middle Aged
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neutropenia / chemically induced*
  • Neutropenia / complications
  • Neutropenia / diagnosis
  • Neutropenia / prevention & control*
  • Ovarian Neoplasms / drug therapy
  • Paclitaxel / adverse effects
  • Prostatic Neoplasms / drug therapy
  • Protective Agents / administration & dosage
  • Protective Agents / therapeutic use*
  • Severity of Illness Index
  • Stomach Neoplasms / drug therapy
  • Taxoids / administration & dosage
  • Taxoids / adverse effects*
  • Tongue Neoplasms / drug therapy

Substances

  • Caproates
  • Imidazoles
  • Protective Agents
  • Taxoids
  • Docetaxel
  • pentanedioic acid imidazolyl ethanamide
  • Paclitaxel